Current Edition

Atea

Roche cuts ties with Atea after COVID-19 pill’s trial failure

Roche’s seeming lack of confidence in the future of AT-527 appears to be weighing on investors. Atea shares, which soared above $88 in February 2021, …

Continue Reading →
Atea

Atea, Roche change plans for oral COVID-19 drug after trial setback

Atea’s fast ascent last year was due to its plan to use a pill originally developed for hepatitis C infections as a treatment for COVID-19. …

Continue Reading →